Medications That May Cause Tardive Dyskinesia: 5 to Know

Some commonly used medications can cause tardive dyskinesia (TD), a movement disorder that may be preventable with early action.

This guide explains five medications linked to TD, what early symptoms look like, how it’s treated, and when to see a doctor—so you can protect your health while still getting the benefits of necessary medicines.

5 Medications Linked to Tardive Dyskinesia

TD most often occurs after long-term use of dopamine-receptor–blocking agents (DRBAs), especially certain antipsychotics and some anti-nausea or stomach medications. Not everyone who takes these drugs will develop TD, but risk rises with higher doses, longer duration, and certain factors like older age, female sex, and diabetes. For a clinical overview of TD, see the National Institute of Neurological Disorders and Stroke’s page on tardive dyskinesia.

1. Haloperidol (Haldol): A first-generation (typical) antipsychotic used for schizophrenia and acute agitation. It strongly blocks dopamine D2 receptors and carries a relatively higher TD risk with long-term use. Learn more in the MedlinePlus haloperidol monograph.
2. Risperidone (Risperdal): A second-generation (atypical) antipsychotic for schizophrenia, bipolar disorder, and irritability in autism. Although atypicals generally have lower TD risk than older drugs, TD can still occur—especially at higher doses or with prolonged use. See the MedlinePlus risperidone monograph.
3. Aripiprazole (Abilify): A partial dopamine agonist sometimes thought to be “lower risk,” but TD has been reported. Vigilance is still important, particularly with chronic therapy. Details are in the MedlinePlus aripiprazole monograph.
4. Prochlorperazine (Compazine): Often prescribed for severe nausea, migraines, or vertigo. It’s a phenothiazine that blocks dopamine and can cause TD, particularly with repeated or long-term use. Review the MedlinePlus prochlorperazine monograph.
5. Metoclopramide (Reglan) — the most surprising

Metoclopramide is a stomach and anti-nausea medicine used for reflux and gastroparesis. Many people are surprised to learn it carries an FDA Boxed Warning for tardive dyskinesia, and treatment is generally recommended for no longer than 12 weeks when possible. See the FDA’s safety information for metoclopramide (Reglan).

Early Signs and Common Symptoms

TD often starts subtly, and catching it early can prevent it from becoming persistent.

Watch for new, involuntary movements after weeks to months on a medication that may cause tardive dyskinesia (or after a dose increase). Early signs can be intermittent and may worsen with stress or fatigue.

• Face and mouth: lip smacking, puckering, chewing motions, grimacing, or frequent blinking
• Tongue and jaw: tongue darting, difficulty keeping the tongue still, jaw movements
• Limbs and trunk: fidgeting, toe tapping, twisting, or rocking of the torso
• Speech and swallowing: slurred speech, throat noises, or trouble chewing/swallowing
• Functional impact: trouble eating, speaking, sleeping, or socializing due to movements

Symptoms can fluctuate from day to day. They may lessen when you’re distracted and worsen with anxiety. While many cases improve after stopping the culprit drug, some movements can persist. For a plain-language overview, MedlinePlus offers a helpful summary of tardive dyskinesia.

What To Do and Treatment Options

First steps: never stop a prescription suddenly

Do not stop or change a prescribed medication on your own. Stopping abruptly—especially antipsychotics—can cause serious withdrawal or symptom relapse. Instead, contact the prescriber who knows your history; they can balance benefits and risks and create a safe plan. For context on mental health medications, see the National Institute of Mental Health’s overview of mental health medications.

Medication adjustments that can help

• Reassess necessity and dose: If possible, taper to the lowest effective dose, take drug holidays only if medically appropriate, or discontinue under supervision.
• Switch to a lower-risk agent: Some antipsychotics have lower TD risk. When feasible, clinicians may switch within the class (for example, to agents with lower TD propensity) while maintaining symptom control.
• Start a VMAT2 inhibitor: Two FDA-approved treatments—valbenazine and deutetrabenazine—reduce TD movements for many people.

VMAT2 inhibitors: evidence-based TD treatment

Valbenazine was the first FDA-approved therapy for TD and improves abnormal movements within weeks for many patients; read the FDA announcement on the first TD treatment here. Deutetrabenazine is another option with supportive clinical evidence; see the MedlinePlus deutetrabenazine monograph for indications and safety. These medicines work by modulating dopamine packaging in nerve terminals (via VMAT2), which dampens involuntary movements.

What to expect: Many patients notice improvements by 2–6 weeks, with continued gains over time. Common side effects can include sleepiness and fatigue; dose adjustments and monitoring may be needed, especially if you take other sedating or QT-prolonging medications. Your clinician will review potential interactions and whether these are appropriate for you.

Other supportive options

• Targeted therapies: For focal, function-limiting movements (e.g., jaw, eyelids), clinicians may consider botulinum toxin injections.
• Rehabilitation: Speech-language therapy for chewing/swallowing or voice, and occupational therapy for task-specific strategies.
• Stress and sleep: Relaxation training and consistent sleep can blunt movement fluctuations.
• Medication clean-up: Some anticholinergics can worsen TD; your prescriber may reduce or replace them when appropriate.
• Whole-health measures: Managing diabetes and metabolic health may lower risk and support recovery.

For education and support, the National Alliance on Mental Illness offers a patient-friendly overview of tardive dyskinesia.

When To See a Doctor

Contact your prescriber promptly if you notice new, repetitive movements after starting or increasing a medication that may cause tardive dyskinesia—especially if they affect eating, speaking, or sleep. Don’t wait if you have been taking metoclopramide for more than 12 weeks, develop movements soon after a dose change, or have risk factors such as older age or diabetes.

• Call now: New facial or tongue movements, worsening fidgeting or rocking, or any movement that interferes with daily life
• Urgent care: Trouble swallowing, unintentional weight loss due to chewing problems, or severe emotional distress from symptoms
• Emergency: Difficulty breathing or sudden, severe muscle stiffness—seek immediate care (these could be signs of other serious reactions)

At the visit, your clinician may use a standardized movement rating (such as the AIMS), review all medications and doses, adjust or switch therapies, and discuss VMAT2 inhibitors. If needed, they may refer you to a psychiatrist experienced in movement disorders or a movement-disorder neurologist.

Key Takeaways

• Several medications—especially certain antipsychotics and anti-nausea drugs—can cause tardive dyskinesia.
• Early signs often involve the face, tongue, and jaw; prompt action can prevent persistence.
• Never stop a prescription on your own; work with your prescriber to adjust therapy.
• Evidence-based treatments exist: VMAT2 inhibitors (valbenazine, deutetrabenazine) can significantly reduce movements for many people.
• If you suspect TD, contact your clinician promptly to review options and protect both your mental and physical health.

This article is for general education and is not a substitute for professional medical advice. Always talk to your healthcare provider about your specific situation.